Biogen Leans On Pipeline As Tecfidera, Spinraza See Q4 Sales Dip
Aducanumab Added To 2021 Guidance Amid Approval Optimism
The company sees aducanumab adding a modest boost to sales if approved, but there are another four Phase III programs with some major read-outs coming.
You may also be interested in...
Biogen Acquires Ionis’ Spinal Muscular Atrophy Candidate As Spinraza Loses Its Shine
The firm has stumped up $60m for Ionis’s preclinical antisense asset in spinal muscular atrophy, a potential successor to the slowing Spinraza, which also faces patent expiry in a few years.
Biosimilars Rise Is Cold Comfort For Biogen As Tecfidera Competition Bites
Biosimilars sales rising by 8% to almost $800m in 2020 failed to offset the impact on Biogen of generic competition to its Tecfidera brand in the US.
Aducanumab Approval Decision Delayed: Could This Be Good News?
Even analysts who still doubt the FDA will approve the anti-amyloid antibody as the first disease-modifying Alzheimer’s treatment said aducanumab’s likelihood of approval has improved.